Payment overview · 2025
General Payments
$1,201.76
53 reported records · 10 companies
Healthcare provider profile · identity verified
Jun Yang, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1184891848
Verified facts
What the public records show
CMS Open Payments records show Jun Yang, M.D. received $1,201.76 in general payments during 2025 across 53 reported records.
Gilead Sciences, Inc. accounted for 41.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $494.76 | 41.2% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $181.31 | 15.1% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $144.15 | 12.0% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $128.56 | 10.7% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.05 | 6.4% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.43 | 6.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.77 | 2.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $25.40 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.53 | 1.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.80 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,201.76 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.72 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $128.56 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.15 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $121.15 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $77.05 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $76.43 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 167 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
143 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
263 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
158 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
167 | 86 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 1958 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 1890 | 210 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1782 | 208 |
| Losartan Potassium | Losartan Potassium | 1273 | 142 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 1039 | 110 |
| Montelukast Sodium | Montelukast Sodium | 910 | 169 |
| Tamsulosin Hcl | Tamsulosin Hcl | 778 | 90 |
| Simvastatin | Simvastatin | 768 | 96 |
| Fenofibrate | Fenofibrate,micronized | 752 | 79 |
| Alendronate Sodium | Alendronate Sodium | 716 | 88 |
| Quetiapine Fumarate | Quetiapine Fumarate | 707 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 682 | 73 |
| Donepezil Hcl | Donepezil Hcl | 601 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 573 | 216 |
| Finasteride | Finasteride | 554 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 551 | 60 |
| Meloxicam | Meloxicam | 520 | 201 |
| Glipizide Er | Glipizide | 497 | 57 |
| Acarbose | Acarbose | 455 | 44 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 440 | 50 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 430 | 72 |
| Allopurinol | Allopurinol | 379 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 364 | 64 |
| Omeprazole | Omeprazole | 362 | 146 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 348 | 228 |
| Hydrochlorothiazide | Hydrochlorothiazide | 344 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 292 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 284 | 101 |
| Metformin Hcl Er | Metformin Hcl | 284 | 42 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 280 | 88 |
| Farxiga | Dapagliflozin Propanediol | 263 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 259 | 121 |
| Gabapentin | Gabapentin | 250 | 66 |
| Metformin Hcl | Metformin Hcl | 250 | 34 |
| Folic Acid | Folic Acid | 223 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 57 |
| Jardiance | Empagliflozin | 206 | 23 |
| Halobetasol Propionate | Halobetasol Propionate | 205 | 95 |
| Clopidogrel | Clopidogrel Bisulfate | 204 | 25 |
| Azithromycin | Azithromycin | 194 | 135 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 167 | 86 |
| Spironolactone | Spironolactone | 166 | 18 |
| Januvia | Sitagliptin Phosphate | 159 | 24 |
| Vemlidy | Tenofovir Alafenamide | 158 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 144 | 17 |
| Synthroid | Levothyroxine Sodium | 143 | 16 |
| Atenolol | Atenolol | 142 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 140 | 65 |
| Clobetasol Propionate | Clobetasol Propionate | 139 | 51 |
| Ammonium Lactate | Ammonium Lactate | 138 | 64 |
| Prednisone | Prednisone | 138 | 80 |
| Carvedilol | Carvedilol | 137 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 128 | 58 |
| Diclofenac Epolamine | Diclofenac Epolamine | 126 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 126 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 125 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 107 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 106 | 11 |
| Hydrocortisone | Hydrocortisone | 102 | 30 |
| Tradjenta | Linagliptin | 102 | 13 |
| Glimepiride | Glimepiride | 100 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 100 | 12 |
| Promethazine Hcl | Promethazine Hcl | 99 | 75 |
| Baclofen | Baclofen | 95 | 47 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 93 | 47 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 92 | 17 |
| Alcohol Pads | Alcohol Antiseptic Pads | 88 | 43 |
| Calcitriol | Calcitriol | 85 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 41 |
| Nortriptyline Hcl | Nortriptyline Hcl | 75 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 74 | 16 |
| Meclizine Hcl | Meclizine Hcl | 72 | 42 |
| Nitroglycerin | Nitroglycerin | 71 | 32 |
| Gemfibrozil | Gemfibrozil | 67 | suppressed |
| Nifedipine Er | Nifedipine | 67 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 66 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 16 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 61 | suppressed |
| Ibuprofen | Ibuprofen | 60 | 53 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 18 |
| Lactulose | Lactulose | 57 | 18 |
| Metronidazole | Metronidazole | 56 | 44 |
| Procto-Med Hc | Hydrocortisone | 56 | 25 |
| Mometasone Furoate | Mometasone Furoate | 55 | 25 |
| Dexlansoprazole Dr | Dexlansoprazole | 53 | 15 |
| Levofloxacin | Levofloxacin | 53 | 42 |
| Ciclopirox | Ciclopirox Olamine | 52 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 50 | 17 |
| Jentadueto | Linagliptin/Metformin Hcl | 47 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 13 |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 43 | suppressed |
| Mupirocin | Mupirocin | 41 | 35 |
| Bepotastine Besilate | Bepotastine Besilate | 39 | 16 |
| Amoxicillin | Amoxicillin | 38 | 29 |
| Ketoconazole | Ketoconazole | 37 | 16 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 35 | 14 |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 34 | suppressed |
| Clarithromycin | Clarithromycin | 32 | 24 |
| Eliquis | Apixaban | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 30 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 30 | 29 |
| Azelastine Hcl | Azelastine Hcl | 29 | 17 |
| Benzonatate | Benzonatate | 25 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Colchicine | Colchicine | 25 | 17 |
| Furosemide | Furosemide | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | 18 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 23 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Famotidine | Famotidine | 22 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Tacrolimus | Tacrolimus | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 19 |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 18 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,201.76 · 53 records | Gilead Sciences, Inc. | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, IBSRELA, NEXLETOL, OTEZLA, REPATHA, SHINGRIX, TAVNEOS, UBRELVY, VOQUEZNA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error